Navigation Links
Innolife Pharma Inc. acquires rights to breakthrough in non-narcotic chronic pain treatment
Date:5/20/2008

Relief soon to be widely available for chronic pain sufferers.

MARKHAM, ON, May 20 /PRNewswire-FirstCall/ - Innolife Pharma, Inc. (Other OTC:INNP.PK - News) is pleased to announce that it has acquired North American licensing rights to the Natural Pain Relief Center non-narcotic proprietary breakthrough in the treatment of chronic pain.

Today, one in five Americans suffer with chronic pain (~ 60 million adults) spending approximately $120 Billion a year and the aging baby boomers have reported in surveys more aches and pains than any previous generation.

New Medical Finding with Brain Scans and Functional MRI's

Modern Brain Imaging has revealed that most chronic pain is the result of the brain's inability to turn off pain messages from the body. In chronic pain the brain simply is not producing and releasing enough natural pain killers (such as endorphins) to stop the person's suffering. These new medical findings show that chronic pain sufferers from headaches, migraines, fibromyalgia, back pain, sciatica, arthritis or a combination of all of them, are caused by a low level of Natural Pain Killer's (such as Endorphins and others) in the brain, as compared to people without chronic pain.

Over three years of in-clinic testing showed that this breakthrough all-natural program relieved significant chronic pain in 8 out of 10 people and with sustainable results. This non-narcotic, combination treatment has been receiving accolades from chronic pain sufferers with major improvement in mood and energy and dramatic decreases in pain levels, allowing a return to normal life function.

Innolife Pharma Inc. has an aggressive growth plan in place with a projected target of 95 licensed clinics in 3 years with projected top line annual revenue in excess of $30 million and a projected bottom line profit of over $12 million annually (40+%).

With the aging demographic, chronic pain is becoming a larger and larger international epidemic. Innolife Pharma Inc. is positioned to be the leading service provider in this segment - with a business model that is designed to provide excellent operating margins and tremendous growth for many years to come.

About Innolife Pharma Inc.

Innolife Pharma Inc. (PINKSHEETS: INNP) is a small publicly traded specialty multi-discipline medical group focusing on licensing the Natural Pain Relief Center all-natural proprietary breakthrough in the treatment of chronic pain.

FORWARD-LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE Innolife Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: